RGD Reference Report - Correlation between gamma-glutamyl transpeptidase activity and outcomes after Kasai portoenterostomy for biliary atresia. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Correlation between gamma-glutamyl transpeptidase activity and outcomes after Kasai portoenterostomy for biliary atresia.

Authors: Ihn, Kyong  Ho, In Geol  Chang, Eun Young  Han, Seok Joo 
Citation: Ihn K, etal., J Pediatr Surg. 2018 Mar;53(3):461-467. doi: 10.1016/j.jpedsurg.2017.10.001. Epub 2017 Oct 6.
RGD ID: 14701039
Pubmed: PMID:29056230   (View Abstract at PubMed)
DOI: DOI:10.1016/j.jpedsurg.2017.10.001   (Journal Full-text)


BACKGROUND/PURPOSE: The role of serum gamma-glutamyl transpeptidase (GGT) levels in predicting clinical outcomes after Kasai portoenterostomy (KPE) is unknown. This study analyzed whether postoperative GGT along with the aspartate aminotransferase-to-platelet ratio index (APRi) predicted prognosis of biliary atresia (BA).
METHODS: Data were retrospectively reviewed for 169 BA patients categorized into jaundice-free (JF) (total bilirubin <2.0 mg/dL <=6 months post-KPE) and persistent jaundice (PJ) groups (total bilirubin >=2.0 mg/dL <=6 months post-KPE). Serum biochemical markers, including GGT levels, were measured monthly after KPE, and mean GGT levels and APRi were compared between groups. Factors predicting native liver survival (NLS) were determined using a Cox regression analysis.
RESULTS: GGT concentrations >550 IU/L at month 5 (hazard ratio: 1.74, P < 0.05), an APRi >0.605 at month 4 (hazard ratio: 3.78, P = 0.001), and being jaundice-free at 6 months (hazard ratio: 5.49, P < 0.001) were independent risk factors for decreased NLS.
CONCLUSIONS: Serum GGT concentrations >550 IU/L at month 5 and an APRi >0.605 at month 4 post-KPE were associated with significantly lower NLS rates. Among JF patients, those with GGT concentrations >550 IU/L at month 5 and APRi >0.605 at month 4 showed poorer outcomes.
TYPE OF STUDY: Retrospective comparative study LEVEL OF EVIDENCE: Level III.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
GGT1Humanbiliary atresia disease_progressionIEP  RGD 
Ggt1Ratbiliary atresia disease_progressionISOGGT1 (Homo sapiens) RGD 
Ggt1Mousebiliary atresia disease_progressionISOGGT1 (Homo sapiens) RGD 

Objects Annotated

Genes (Rattus norvegicus)
Ggt1  (gamma-glutamyltransferase 1)

Genes (Mus musculus)
Ggt1  (gamma-glutamyltransferase 1)

Genes (Homo sapiens)
GGT1  (gamma-glutamyltransferase 1)


Additional Information